Cullinan Therapeutics, Inc. (CGEM)
(Delayed Data from NSDQ)
$16.78 USD
+0.47 (2.88%)
Updated Jul 3, 2024 01:00 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Cullinan Therapeutics, Inc. [CGEM]
Reports for Purchase
Showing records 1 - 20 ( 56 total )
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Where the Brook Is Deep; State of Acute Myeloid Leukemia Treatment
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CLN-619 Data Presentations at ASCO 2024; Positive Initial Data From REZILIENT1 Study of Zipalertinib
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
So Far, So Good; Zipalertinib, CLN-619 Data Updates
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology -ASCO 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase 1 Dose Escalation Data for CLN-619 to be Presented at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Multiple Pipeline Data Readouts in 2024 Could Move the Stock Higher
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Having the Upper Hand on Blincyto Has Never Been So Valuable
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- ASCO 2024 Abstract Titles for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Moving Into Autoimmune Diseases With CLN-978; Private Placement Announced; Lowering PT to $29
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results; Pivotal Zipalertinib Trial Expected to be Fully Enrolled by YE24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E